The Department of Justice has added another set of kickback allegations to its lawsuit against Novartis. In April, the feds accused the Swiss drugmaker of using pharmacy kickbacks to increase sales of its transplant drug Myfortic. Now, the alleged pharmacy kickbacks involve a different drug—the iron chelation therapy Exjade.
Novartis is reportedly in talks with Merck & Co. to trade its vaccines and animal health businesses for Merck & Co.'s consumer health operations.
Here's a plan that would kill two birds with one stone: Novartis and Merck are negotiating a swap, Bloomberg reports. Novartis would trade its animal health and vaccines units for Merck's consumer health business.
The meningitis B outbreak at the University of California, Santa Barbara, has slowed for now, with no new cases on the campus since November. However, authorities still view the bacteria as a threat and are trying to get clearance to use Novartis' Bexsero. When that will happen is unclear, though.
The recently IPO'd Foundation Medicine has expanded its relationship with Novartis, lending out its gene-profiling technology to help the drugmaker develop cancer treatments.
The Diovan data scandal in Japan has spawned a criminal action against Novartis. The country's Health Ministry lodged a complaint against Novartis today, accusing its domestic unit of exaggerated advertising.
Diagnostics luminary Foundation Medicine has expanded its relationship with pharma giant Novartis, giving the drugmaker more access to its gene profiling technology to develop cancer treatments.
Sanofi has been slammed against the regulatory wall at the FDA, picking up a stinging rejection of its multiple sclerosis drug Lemtrada with orders to go back to the clinic for a major round of new trial work if the company ever expects to get the drug over the U.S. finish line at some point.
Californian health officials have asked for permission to use Novartis' unapproved meningitis B vaccine Bexsero to control an outbreak at a college.
GlaxoSmithKline's Advair is not your average off-patent blockbuster. It's difficult to copy, which has held off any major generic competition to date. Now, Novartis' generics unit Sandoz and its partner, Vectura, have won their first approval for a copy of the top-selling lung med--a reminder that the clock is ticking on Advair's turn at the top.